Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EBT (2018 - 2025)

Historic EBT for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$29.8 million.

  • X4 Pharmaceuticals' EBT rose 1863.64% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.8 million, marking a year-over-year decrease of 46852.58%. This contributed to the annual value of -$37.1 million for FY2024, which is 6326.01% up from last year.
  • X4 Pharmaceuticals' EBT amounted to -$29.8 million in Q3 2025, which was up 1863.64% from -$25.7 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year EBT high stood at $90.9 million for Q2 2024, and its period low was -$55.7 million during Q2 2023.
  • Its 5-year average for EBT is -$19.8 million, with a median of -$21.9 million in 2022.
  • Within the past 5 years, the most significant YoY rise in X4 Pharmaceuticals' EBT was 26311.65% (2024), while the steepest drop was 150952.17% (2024).
  • Over the past 5 years, X4 Pharmaceuticals' EBT (Quarter) stood at -$30.2 million in 2021, then grew by 3.69% to -$29.1 million in 2022, then soared by 34.35% to -$19.1 million in 2023, then tumbled by 107.17% to -$39.6 million in 2024, then grew by 24.56% to -$29.8 million in 2025.
  • Its EBT stands at -$29.8 million for Q3 2025, versus -$25.7 million for Q2 2025 and $316000.0 for Q1 2025.